COMBINATION TREATING PROSTATE CANCER, PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD
Disclosed are a combination treating prostate cancer, a pharmaceutical composition and a treatment method. The combination includes one of a benzoheterocyclic compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, a crystalline form thereof, a co-crystal the...
Gespeichert in:
Hauptverfasser: | , , |
---|---|
Format: | Patent |
Sprache: | eng ; fre |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | GE, CHUANSHENG LEE, WENRNG LIAO, BAISONG |
description | Disclosed are a combination treating prostate cancer, a pharmaceutical composition and a treatment method. The combination includes one of a benzoheterocyclic compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, a crystalline form thereof, a co-crystal thereof, a stereoisomer thereof, an isotope compound thereof, a metabolite thereof and a prodrug thereof, and an androgen receptor pathway modulator. The combination, the pharmaceutical composition thereof and the treatment method inhibit prostate cancer in a more effective manner. (see formula I)
L'invention concerne une association médicamenteuse pour le traitement du cancer de la prostate, une composition pharmaceutique et une méthode de traitement. L'association médicamenteuse comprend un composé benzohétérocyclique tel que représenté par la formule (I), un sel pharmaceutiquement acceptable de celui-ci, un solvate de celui-ci, une forme cristalline de celui-ci, un co-cristal de celui-ci, un stéréoisomère de celui-ci, un composé isotope de celui-ci, un métabolite de celui-ci et un promédicament de celui-ci, et un modulateur de la voie du récepteur androgène. L'association médicamenteuse, la composition pharmaceutique associée et la méthode de traitement inhibent le cancer de la prostate de manière plus efficace. |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA3053805C</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA3053805C</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA3053805C3</originalsourceid><addsrcrecordid>eNrjZAh19vd18vRzDPH091MICXIFMvzcFQKC_INDHENcFZwd_Zxdg3QUAjwcg3wdnV1DQzydHX0UgJoC_IM9wZoc_VwgGn1d_UIUfF1DPPxdeBhY0xJzilN5oTQ3g7yba4izh25qQX58anFBYnJqXmpJvLOjsYGpsYWBqbMxYRUAyvAvzA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>COMBINATION TREATING PROSTATE CANCER, PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD</title><source>esp@cenet</source><creator>GE, CHUANSHENG ; LEE, WENRNG ; LIAO, BAISONG</creator><creatorcontrib>GE, CHUANSHENG ; LEE, WENRNG ; LIAO, BAISONG</creatorcontrib><description>Disclosed are a combination treating prostate cancer, a pharmaceutical composition and a treatment method. The combination includes one of a benzoheterocyclic compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, a crystalline form thereof, a co-crystal thereof, a stereoisomer thereof, an isotope compound thereof, a metabolite thereof and a prodrug thereof, and an androgen receptor pathway modulator. The combination, the pharmaceutical composition thereof and the treatment method inhibit prostate cancer in a more effective manner. (see formula I)
L'invention concerne une association médicamenteuse pour le traitement du cancer de la prostate, une composition pharmaceutique et une méthode de traitement. L'association médicamenteuse comprend un composé benzohétérocyclique tel que représenté par la formule (I), un sel pharmaceutiquement acceptable de celui-ci, un solvate de celui-ci, une forme cristalline de celui-ci, un co-cristal de celui-ci, un stéréoisomère de celui-ci, un composé isotope de celui-ci, un métabolite de celui-ci et un promédicament de celui-ci, et un modulateur de la voie du récepteur androgène. L'association médicamenteuse, la composition pharmaceutique associée et la méthode de traitement inhibent le cancer de la prostate de manière plus efficace.</description><language>eng ; fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200630&DB=EPODOC&CC=CA&NR=3053805C$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200630&DB=EPODOC&CC=CA&NR=3053805C$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>GE, CHUANSHENG</creatorcontrib><creatorcontrib>LEE, WENRNG</creatorcontrib><creatorcontrib>LIAO, BAISONG</creatorcontrib><title>COMBINATION TREATING PROSTATE CANCER, PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD</title><description>Disclosed are a combination treating prostate cancer, a pharmaceutical composition and a treatment method. The combination includes one of a benzoheterocyclic compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, a crystalline form thereof, a co-crystal thereof, a stereoisomer thereof, an isotope compound thereof, a metabolite thereof and a prodrug thereof, and an androgen receptor pathway modulator. The combination, the pharmaceutical composition thereof and the treatment method inhibit prostate cancer in a more effective manner. (see formula I)
L'invention concerne une association médicamenteuse pour le traitement du cancer de la prostate, une composition pharmaceutique et une méthode de traitement. L'association médicamenteuse comprend un composé benzohétérocyclique tel que représenté par la formule (I), un sel pharmaceutiquement acceptable de celui-ci, un solvate de celui-ci, une forme cristalline de celui-ci, un co-cristal de celui-ci, un stéréoisomère de celui-ci, un composé isotope de celui-ci, un métabolite de celui-ci et un promédicament de celui-ci, et un modulateur de la voie du récepteur androgène. L'association médicamenteuse, la composition pharmaceutique associée et la méthode de traitement inhibent le cancer de la prostate de manière plus efficace.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZAh19vd18vRzDPH091MICXIFMvzcFQKC_INDHENcFZwd_Zxdg3QUAjwcg3wdnV1DQzydHX0UgJoC_IM9wZoc_VwgGn1d_UIUfF1DPPxdeBhY0xJzilN5oTQ3g7yba4izh25qQX58anFBYnJqXmpJvLOjsYGpsYWBqbMxYRUAyvAvzA</recordid><startdate>20200630</startdate><enddate>20200630</enddate><creator>GE, CHUANSHENG</creator><creator>LEE, WENRNG</creator><creator>LIAO, BAISONG</creator><scope>EVB</scope></search><sort><creationdate>20200630</creationdate><title>COMBINATION TREATING PROSTATE CANCER, PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD</title><author>GE, CHUANSHENG ; LEE, WENRNG ; LIAO, BAISONG</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA3053805C3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2020</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>GE, CHUANSHENG</creatorcontrib><creatorcontrib>LEE, WENRNG</creatorcontrib><creatorcontrib>LIAO, BAISONG</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>GE, CHUANSHENG</au><au>LEE, WENRNG</au><au>LIAO, BAISONG</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>COMBINATION TREATING PROSTATE CANCER, PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD</title><date>2020-06-30</date><risdate>2020</risdate><abstract>Disclosed are a combination treating prostate cancer, a pharmaceutical composition and a treatment method. The combination includes one of a benzoheterocyclic compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, a crystalline form thereof, a co-crystal thereof, a stereoisomer thereof, an isotope compound thereof, a metabolite thereof and a prodrug thereof, and an androgen receptor pathway modulator. The combination, the pharmaceutical composition thereof and the treatment method inhibit prostate cancer in a more effective manner. (see formula I)
L'invention concerne une association médicamenteuse pour le traitement du cancer de la prostate, une composition pharmaceutique et une méthode de traitement. L'association médicamenteuse comprend un composé benzohétérocyclique tel que représenté par la formule (I), un sel pharmaceutiquement acceptable de celui-ci, un solvate de celui-ci, une forme cristalline de celui-ci, un co-cristal de celui-ci, un stéréoisomère de celui-ci, un composé isotope de celui-ci, un métabolite de celui-ci et un promédicament de celui-ci, et un modulateur de la voie du récepteur androgène. L'association médicamenteuse, la composition pharmaceutique associée et la méthode de traitement inhibent le cancer de la prostate de manière plus efficace.</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng ; fre |
recordid | cdi_epo_espacenet_CA3053805C |
source | esp@cenet |
subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
title | COMBINATION TREATING PROSTATE CANCER, PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T15%3A49%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=GE,%20CHUANSHENG&rft.date=2020-06-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA3053805C%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |